Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy
Cardiology in Review, 2023Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel +4 more
openaire +2 more sources
Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy
Annals of Pharmacotherapy, 2022Objective: To assess mavacamten’s role in hypertrophic cardiomyopathy treatment. Data Sources: In addition to clinical guidelines, package inserts, and general reviews, we searched PubMed using the term mavacamten from inception to June 11, 2022. Study Selection and Data Extraction: English language studies describing mavacamten’s mechanism of action ...
Joseph D. Dalo +2 more
openaire +2 more sources
Selective cardiac myosin inhibitors protect the heart following ischemia-reperfusion injury
European Heart Journal, 2023Abstract Background/Introduction Following an acute myocardial infarction, reperfusion of an occluded coronary artery is often accompanied by cardiomyocyte injury, leading to a worse long-term prognosis.
L Yusof, D M Yellon, S M Davidson
openaire +1 more source
First-in-class cardiac myosin inhibitor reduces symptoms of HCM
Nature Reviews Cardiology, 2020Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
openaire +2 more sources
Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors
Journal of Cardiothoracic and Vascular AnesthesiaHypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The disease is characterized by asymmetric left ventricular (LV) remodeling with myocyte disarray and interstitial fibrosis, a hypercontractile state, dynamic subaortic obstruction of the LV outflow tract, impaired LV diastolic function, atrial and ventricular arrhythmias ...
Paul S, Pagel +3 more
openaire +2 more sources
Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy
MedA key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these
Milind Y, Desai, Eugene, Braunwald
openaire +2 more sources
The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy
Canadian Journal of CardiologyHypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy worldwide and causes significant morbidity and mortality. For decades, medical treatment options have been limited and untargeted, with frequent need for invasive interventions not readily accessible to many HCM patients.
Rebecca Haraf, Hany Habib, Ahmad Masri
openaire +2 more sources
Cardiac myosin inhibitors for the treatment of obstructive and non-obstructive HCM
Nature Reviews Cardiologyopenaire +3 more sources
Recent trend in the therapy of hypertrophic cardiomyopathy: Cardiac myosin inhibitors
2023Cardiac myosin inhibitors are a new class of drugs that have recently been approved in obstructive hypertrophic cardiomyopathy. The main mechanism of action is to reduce the pathologically increased cardiac hypercontractility. Current drug therapies have not been demonstrated to modify the natural progress of the disease.
DEMİRKIRAN, Cahit +2 more
openaire +1 more source
Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy
JACC: Heart Failure, 2023John W. Ostrominski +3 more
openaire +1 more source